CarcelCSandsetECAliM, et al. Addressing sex and gender differences in stroke risk and management: a scientific statement from the World Stroke Organization. Int J Stroke2025; 21: 303–323.
2.
CaoFLiuJWangYHeQGuoYYanJ.Female hormonal and reproductive factors and the risk of subarachnoid hemorrhage. Int J Stroke2025; 20: 105–115.
3.
ZhouYGisingerTLindnerSD, et al. Sex, gender, and stroke recovery: functional limitations and inpatient care needs in Canadian and European survivors. Int J Stroke2025; 20: 215–225.
4.
MarkoMMiksovaDHaideggerM, et al. Trends in sex differences of functional outcome after intravenous thrombolysis in patients with acute ischemic stroke. Int J Stroke2024; 19: 1147–1154.
5.
Tuna MA, Rothwell PM and Oxford Vascular Study.Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis. Lancet2021; 397: 902–912.
6.
GalloglyPCHassanJLeeC, et al. Clinical features, including atypical symptoms, associated with acute cerebral ischaemia on DWI-MRI in suspected TIA and minor stroke. Int J Stroke2025; 21: 353–361.
7.
LakhaniDASalimHAYedavalliVInvestigatorsMADMT. Factors associated with early neurological deterioration in minor distal medium vessel acute ischemic stroke: a multinational multicenter study. Int J Stroke2025; 21: 343–352.
8.
QiaoYZhaoMWangJ, et al. Stroke etiology was associated with tirofiban efficacy in acute ischemic stroke without endovascular treatment: a pre-specified subgroup analysis of the TREND trial. Int J Stroke2025; 20: 977–986.
9.
ZhengLLiuYNieX, et al. Intravenous tirofiban following endovascular therapy for patients with acute large vessel occlusion stroke. Int J Stroke. Epub ahead of print 29 September 2025. DOI: 10.1177/17474930251386577.
10.
WerringDJOzkanHDoubalF, et al. Early neurological deterioration in acute lacunar ischemic stroke: systematic review of incidence, mechanisms, and prospects for treatment. Int J Stroke2025; 20: 7–20.
11.
ShiYBaiXZhangXPeiXWangYSuiB.Plaque features and lenticulostriate artery morphology in unexplained early neurological deterioration in symptomatic MCA stenosis: a 7 T MRI study. Int J Stroke2025; 20: 1271–1279.
12.
MarkusHSHarshfieldELCompterA, et al. Vertebral Stenosis Trialists’ Collaboration. Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis. Lancet Neurol2019; 18: 666–673.
13.
LiuDWangTXuW, et al. Abstract TP226: drug-eluting stenting versus medical treatment alone for patients with extracranial vertebral artery stenosis: the VISTA trial. Stroke2025; 56. DOI: 10.1161/str.56.suppl_1.TP22.
14.
LuoJJiangCWangH, et al. Effect of drug-coated balloon in patients with severe vertebral artery origin stenosis: a multicenter randomized controlled trial. Int J Stroke2025; 21: 362–371.
15.
MicieliASinghNJahnBSiebertUMenonBKDemchukAM.Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: a Canadian perspective. Int J Stroke2023; 18: 416–425.
16.
NarasimhaluKChanJAngYKDe SilvaDATanKB.Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack. Int J Stroke2024; 19: 209–216.
17.
KremersFCvan den BiggelaarJ, et al. Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: systematic review and meta-analysis. Int J Stroke2025; 21: 324–334.
18.
WangCWangBHanH, et al. Natural history and outcomes of deep-seated brain arteriovenous malformations: a propensity score matched analysis using nationwide multicenter prospective registry data. Int J Stroke2025; 21: 383–397.
